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Signal transduction events leading to the survival, dif-
ferentiation, or apoptosis of cells of the innate or adap-
tive immune system must be properly coordinated to
ensure the normal mounting and termination of im-
mune responses. One of the key transcription factors
in immune responses is nuclear factor kB (NF-kB),
which has been the focus of intense investigation
over the past two decades. With the identification of
the CARMA1-BCL10-MALT1 complex and ongoing
progress in understanding themolecular mechanisms
connecting T cell and B cell receptor proximal signals
to the IkB kinase (IKK) complex, a cohesive model of
antigen receptor (AgR)-dependent signaling to NF-kB
activation is beginning to emerge. In this review, we
provide an overview of the current state of research
into the mechanisms that regulate AgR-mediated
NF-kB transcriptional activity, with particular focus
on the events leading to activation of the IKK complex.
Introduction
The transcription factor NF-kB regulates various as-
pects of immune-cell development, homeostasis, sur-
vival, and function. Pathogen recognition, whether me-
diated through the Toll-like receptors of the innate
immune system (for detailed reviews see Kawai and
Akira, 2006; West et al., 2006) or through the antigen-
specific T and B cell receptors (TCR and BCR) of the
adaptive immune system, triggers distinct signal-trans-
duction pathways that lead to the activation of NF-kB.
Numerous genetic models in mice have confirmed the
essential role of this transcription factor in promoting T
and B cell activation, expansion, and effector function
in response to infection (Bonizzi and Karin, 2004; Hay-
den and Ghosh, 2004). Moreover, dysregulated NF-kB
activation either via the amplification of Rel genes or
via aberrant activation of upstream regulators contrib-
utes to the development of autoimmunity, chronic in-
flammation, and cancer (Karin, 2006; Karin and Greten,
2005). The molecular mechanisms controlling NF-kB ac-
tivation in lymphocytes are therefore currently the focus
of intense research.
First described in nuclei of B cells, NF-kB has since
been shown to exist in an inactive cytosolic form in all
cell types. Upon activation by any of a large number of
inducers, NF-kB rapidly translocates into the nucleus
and engages its cognate kB enhancer elements up-
stream of various target genes. NF-kB represents a
group of structurally related and evolutionarily con-
served proteins (also known as the Rel family) with five
members in mammals: RelA (p65), RelB, c-Rel (REL),
*Correspondence: sankar.ghosh@yale.eduNF-kB1 (p50 and its precursor p105), and NF-kB2 (p52
and its precursor p100). The proteins share an N-termi-
nal Rel homology domain (RHD) of approximately 300
amino acids, which includes sequences responsible
for dimerization, interaction with inhibitor of NF-kB (IkB)
inhibitory proteins, nuclear translocation, and DNA bind-
ing. In resting cells most members of this family form
both homodimers and heterodimers bound to IkB family
proteins in the cytosol and thereby prevent the complex
from shuttling to the nucleus and hence maintain NF-kB
in an inactive state.
The mammalian NF-kB proteins can be broadly classi-
fied into two groups. One group includes RelA, RelB, and
c-Rel, which are expressed as mature proteins contain-
ing a C-terminal transcriptional activation domain (TAD)
(Ghosh and Karin, 2002). The second group consists of
NF-kB1 (p50) and NF-kB2 (p52), which are at first ex-
pressed as large precursor proteins of 105 and 100
kDa, respectively, and undergo proteolytic processing
to generate the smaller forms. Both p50 and p52 lack
transactivation domains, and therefore homodimers of
these proteins cannot drive transcription. The NF-kB
precursors p100 and p105 can also function as IkBs
through their C-terminal ankyrin repeats and retain the
Rel proteins in the cytoplasm (Ghosh and Karin, 2002).
There are nine IkB family members, which can be divided
into three subgroups: (1) the classical IkBs a, b, g (p70),
and 3; (2) the NF-kB precursors p105 and p100; and (3)
the unusual IkBs, B cell leukemia/lymphoma (BCL)-3,
IkBz and IkBNS. Inhibitory IkB proteins are characterized
by the presence of five to seven ankyrin repeats that al-
low protein-protein interactions with NF-kB dimers,
thereby masking at least one of the nuclear localization
signals (NLS) in the RHD of NF-kBs. In addition, IkBa
blocks DNA binding and promotes nuclear export of as-
sociated NF-kB dimers through an N-terminal export se-
quence (Hayden and Ghosh, 2004; Schmitz et al., 2004).
NF-kB signaling occurs through either the classical
(also known as canonical) or alternative (also known as
noncanonical, nonclassical, or novel) pathway (Bonizzi
and Karin, 2004; Ghosh and Karin, 2002). Whereas the
classical pathway is IkB kinase (IKK) b and IKKg (also
knownasNF-kB essential modulator– NEMO)dependent
and NF-kB activation occurs through IkB degradation (Li
and Verma, 2002), the alternative pathway depends on
IKKa- and NF-kB-inducing kinase (NIK) and is based on
regulated processing of the p100 precursor protein
(Senftleben et al., 2001; Xiao et al., 2001). This alternative
pathway is involved in NF-kB activation after stimulation
of the tumor necrosis factor (TNF) superfamily members
B cell activating factor (BAFF), lymphotoxin b, and CD40
ligand and is particularly important for B cell maturation
and lymphoid organ formation (Hayden et al., 2006).
Degradation of IkB is a tightly controlled process that
is initiated upon specific phosphorylation on two con-
served N-terminal serine residues by the activated IKK
complex. This 700–900 kDa complex is composed of at
least three subunits: two catalytic kinase subunits, IKKa
(IKK1) and IKKb (IKK2), and a structural as well as regu-
latory subunit, IKKg (NEMO). Phosphorylated IkB is
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702Table 1. Characteristics of Mouse Models and Gene-Deficient Cell Lines for AgR-Mediated IKK Activation
Knockout Gene T and B Cell Phenotype References
TCR-Proximal Signaling Components
Fyn TCR signaling defect in mouse thymocytes, impaired
PKCq/NF-kB activation
(Appleby et al., 1992; Cannons et al., 2004)
ZAP70 Abolished TCR-mediated PKCq/NF-kB activation in
deficient Jurkat cell line
(Herndon et al., 2001)
SLP76/ PLCg1 Abolished TCR-mediated PKCq lipid-raft recruitment and
NF-kB activation in deficient Jurkat cell line
(Dienz et al., 2003)
SAP Crucial role in murine CD4+ T cell function, essential for
late B cell help and long-term humoral immunity
(Crotty et al., 2003)
Vav1 Critical role in T cell development and activation; TCR-induced
calcium flux, activation of ERK and NF-kB, TCR clustering
(Tybulewicz, 2005)
IRAK4 Reduced proliferation, IL-2 synthesis, and NF-kB activation
after TCR stimulation
(Suzuki et al., 2006)
PKCq Normal T cell development, impaired proliferation, IL-2
synthesis and activation of NF-kB, AP-1, and NFAT
after TCR costimulation
(Pfeifhofer et al., 2003; Sun et al., 2000)
BCR-Proximal Signaling Components
Lyn Impaired B cell development and pre-BCR-mediated
NF-kB activation
(Saijo et al., 2003)
Syk Impaired NF-kB and PLCg2 activation, calcium mobilization,
and developmental defects in mouse IIA1.6/A20 B cells
(Yokozeki et al., 2003)
SLP65 Defect in BCR-mediated NF-kB activation and proliferation (Koretzky et al., 2006; Tan et al., 2001)
Btk Reduced B1 cells, impaired BCR mediated NF-kB
activation and proliferation
(Petro et al., 2000)
PLCg2 Reduced mature B cells and B1 cells, impaired
BCR-mediated proliferation, survival
(Hikida et al., 2003)
PKCb Reduced numbers of B1 cells, impaired NF-kB activation
and proliferation after BCR/CD40 engagement
(Saijo et al., 2002; Su et al., 2002)
CBM Complex:
CARMA1 Reduced numbers of mature B cells and B1 cells,
impaired BCR-CD40-mediated proliferation, NF-kB
and JNK activation, impaired TCR-mediated
proliferation, IL-2 synthesis, NF-kB and JNK activation
(Egawa et al., 2003; Hara et al., 2003;
Jun et al., 2003; Newton and Dixit, 2003;
Pomerantz et al., 2002;
Wang et al., 2002)
BCL10 Reduced B1 cells, impaired BCR-CD40-mediated proliferation
and NF-kB activation, impaired TCR-mediated proliferation,
IL-2 synthesis, and NF-kB activation
(Ruland et al., 2001; Xue et al., 2003)
RIP2 Partially impaired TCR-mediated proliferation, IL-2 synthesis
and NF-kB activation, impaired TH1 differentiation, impaired
IFNg production in TH1 and NK cells
(Chin et al., 2002; Kobayashi et al., 2002;
Ruefli-Brasse et al., 2004)
MALT1 Reduced peritoneal B1 cells, impaired BCR-CD40-mediated
proliferation, impaired TCR-mediated proliferation,
IL-2 synthesis, and NF-kB activation
(Ruefli-Brasse et al., 2003;
Ruland et al., 2003)marked for E2- and E3-ligase-mediated polyubiquitina-
tion and subsequently for 26S proteosomal degradation,
freeing and thereby activating NF-kB (Li and Verma,
2002). The function of the Rel protein TADs (e.g., recruit-
ment of coactivators and displacement of repressors
after DNA binding) is enhanced through direct post-
translational modifications, including phosphorylation
(Zhong et al., 1998) and acetylation, and therefore
provides another layer of regulation of NF-kB-mediated
responses (for reviews, see Chen and Greene, 2004;
Schmitz et al., 2004). It should be noted that the connec-
tion between TCR and BCR activation and specific
nuclear modifications of NF-kB subunits is currently
poorly understood.
Activated NF-kB can be downregulated through mul-
tiple mechanisms including the well-characterized feed-
back loop involving newly synthesized IkBa, which
binds to nuclear NF-kB and thus removes it from DNA
and exports it to the cytosol (Hayden and Ghosh,
2004). Eventually the quiescent state of the cell is re-stored, ensuring that the cell can respond to other extra-
cellular stimuli (Bonizzi and Karin, 2004).
Various receptors activate NF-kB through signal-
transduction pathways that appear to be quite distinct.
A number of genetic studies have identified signaling in-
termediates involved in the BCR- and TCR-mediated
activation of the IKK complex (Table 1). Numerous bio-
chemical studies have established a putative model of
IKK activation through these effectors; in this model,
protein kinase C q (PKCq) in T cells and PKCb in B cells
act upstream of a trimolecular protein complex CARMA1
(also known as CARD11)-BCL10-MALT1 (referred to as
the CBM complex) to promote NEMO polyubiquitination
and consequent IKK activation. The events that occur
downstream of the IKK complex, however, are not spe-
cific for lymphocytes and appear to be similar to those
in most NF-kB-activating pathways. Therefore, we will
primarily focus our discussion on events that link anti-
gen receptors to the IKK complex during lymphocyte
activation.
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BCR-Induced NF-kB Activation
Engagement of TCRs induces the formation of an or-
dered, membrane-associated complex referred to as
the immunological synapse in which a central signaling
zone surrounds clustered TCRs. These ‘‘supramolecular
activation clusters’’ (SMAC) can be subdivided into the
central SMAC (cSMAC) and peripheral SMAC (pSMAC).
The TCR-CD3 complex, as well as CD28, is localized to
the cSMAC, whereas other signaling proteins appear to
be recruited to one or the other of these distinct regions
where they can transmit distinct signals (Monks et al.,
1998). Most of the signaling intermediates relevant to
NF-kB activation become clustered in the cSMAC. It
should be mentioned that a homologous synaptic struc-
ture is formed in B cells and that many highly similar mo-
lecular events are activated after BCR engagement
(Batista et al., 2001).
The antigen receptor complexes associate with pro-
tein tyrosine kinases (PTKs) of the Src family (SFKs):
Lck (bound to the cytosolic site of CD4 or CD8 corecep-
tors) and Fyn in T cells and Blk, Fyn, and Lyn in B cells
(Figure 1). SFKs in both cell types associate with the
phosphatase CD45 that facilitates activation of SFKs
by removing phosphates from inhibitory tyrosine resi-
dues. After receptor engagement, SFKs phosphorylate
conserved immunoreceptor tyrosine activation motifs
(ITAMs) on CD3 or Iga and Igb chains. The cytoplasmic
Syk family tyrosine kinases ZAP70 and Syk are then re-
cruited via SH2 domains to the phosphorylated ITAMs of
the TCR or BCR complexes, respectively. ZAP70 and
Syk, in turn, phosphorylate several substrates, including
the transmembrane adaptor molecules LAT and LAB
and the cytosolic adaptor proteins SLP76 and SLP65
(also known as BLNK) in T and B lymphocytes (Weil
and Israel, 2004). These proteins then serve as docking
surfaces for other adaptors such as Grb2, GADS,
Bam32, the p85 regulatory subunit of phosphatidylinosi-
tol-3 kinase (PI3K), and phospholipase Cg (PLCg). Addi-
tionally, the Tec family members Itk and Bruton’s tyro-
sine kinase (Btk) become activated. A multiprotein
signaling complex is ultimately formed, and its forma-
tion leads to activation of the inositol-1,4,5-triphosphate
(IP3) and Ras family pathways (Figure 1).
The CD28 Coreceptor in TCR Signaling to NF-kB
Activation of only the TCR leads to weak activation of
NF-kB, and signals from the CD28 coreceptor are nec-
essary to produce full T cell and NF-kB activation
(Kane et al., 2002a). CD28 is engaged by its ligands
B7-1 (CD80) and B7-2 (CD86) on APCs and most likely
helps augment the TCR signal rather than delivering
a unique second signal (Schmitz and Krappmann, 2006).
The link between NF-kB and CD28 was suggested by
the demonstration of NF-kB binding to the CD28-re-
sponsive element (CD28 RE) in the IL-2 promoter (Ver-
weij et al., 1991). It appears that CD28 coengagement
can signal to NF-kB through two different pathways (Fig-
ure 1) (Schmitz and Krappmann, 2006). The first pathway
involves PI3K-dependent signaling that is initiated upon
recruitment of the p85 regulatory PI3K subunit to the
CD28 coreceptor. This allows SH3 domain-dependent
binding and activation of Rho-family GTPases as well
as activation of PI3K. Activated PI3K leads to the gener-ation of the second-messenger molecules PIP2 and
PIP3, which are localized to the inner leaflet of the
plasma membrane and bind various pleckstrin homol-
ogy domain (PHD)-containing proteins, including phos-
phatidylinositol-dependent kinase 1 (PDK1, discussed
later), protein kinase B (PKB also known as Akt), and
the guanine nucleotide exchange factor (GEF) Vav (Lem-
mon, 2005). Transgenic mice expressing a constitutively
active form of PKB show increased NF-kB activity after
CD28 engagement, suggesting its importance in TCR-
CD28-mediated NF-kB activation (Jones et al., 2000).
One pathway of transmitting PKB-derived signals to
NF-kB starts with the phosphorylation of the serine-
threonine kinase Cot (also known as Tpl2), which leads
to NIK-dependent activation of the IKK signalosome
(Kane et al., 2002b). A study involving overexpression
experiments suggested that NIK might control CD28-
dependent transcription and T cell activation by modu-
lating the phosphorylation of the transcriptional activa-
tion domain (TAD) of c-Rel (Sanchez-Valdepenas et al.,
2006). PKB in cooperation with activated PKCq has
also been implicated in TCR-CD28-mediated binding
to CARMA1 by promoting the phosphorylation of
BCL10 and thereby activating NF-kB (Narayan et al.,
2006). However, definitive demonstration of the impor-
tance of PKB in NF-kB signaling awaits the availability
of cell-specific, PKB-deficient mouse models. MEKK1
and the BCL10-interacting kinase RIP2 have also been
reported to be involved in CD28-triggered IKK-NF-kB
activation; however, the exact molecular targets for
these kinases remain undefined (Ruefli-Brasse et al.,
2004; Tao et al., 2002).
The second pathway linking CD28 to NF-kB activation
utilizes the adaptor protein Grb2. Grb2 lacks any intrin-
sic enzymatic activity but connects signaling intermedi-
ates via its SH2 and SH3 domains. Most crucial for T cell
costimulatory signals is the interaction of Grb2 and Vav
(Fujikawa et al., 2003). Costimulation results in pro-
longed and sustained tyrosine phosphorylation and
membrane localization of Vav in comparison to TCR
stimulation alone (Hehner et al., 2000). Vav therefore
seems to function as a signal integrator receiving input
from CD28 as well as from the TCR. Once activated,
Vav signals in many directions: The GEF activity leads
through Rac and Rho to actin cytoskeleton reorganiza-
tion, whereas the membrane-associated Vav-SLP76
complex leads to activation of PLCg and consequent re-
lease of diacylglycerol (DAG), which is important for
transmitting the TCR-CD28 signal to PKCq (Villalba
et al., 2002). Vav binds to IKKa to recruit it to the mem-
brane and activate it in response to CD28 stimulation
(Piccolella et al., 2003). In addition to its involvement in
the TCR-CD28-mediated NF-kB pathway, Vav is also
important for activation of NFAT, AP1, and JNK, as
well as for sustained Ca2+ signaling (Cao et al., 2002;
Costello et al., 1999).
The Importance of PKC Members in Antigen-
Receptor Signaling to NF-kB
Whereas the early Ag receptor signals are transduced
by successive tyrosine phosphorylation events, gen-
eration of DAG and IP3 by PLCg leads to a shift in the
nature of modifications used to transmit the signal fur-
ther. Serine and threonine phosphorylation and lysine
Immunity
704Figure 1. Early Signaling Events in Antigen-Receptor-Mediated NF-kB Activation
(A) Binding of TCR to peptide-MHC and costimulation through CD28-B7 interaction leads to PKCq-mediated CARMA1 phosphorylation. Through
multiple steps, initial tyrosine phosphorylation events at the TCR complex lead to PLCg1 and PI3K activation. PI3K promotes recruitment of
PDK1, which in turn mediates recruitment of the IKK complex through PKCq and CARMA1. PKCq phosphorylates CARMA1, leading to an active
CARMA1 conformation with accessible protein-interaction sites. At the same time, BCL10 is phosphorylated in cytosolic POLKADOTs, perhaps
by RIP2, and starts to associate with MALT1.
(B) Receptor-proximal events of BCR activation are highly analogous to those of the TCR. Although the role of PDK1 in B cell signaling is not
established, BCR signaling to NF-kB requires PLCg2 and PKCb as well as the CBM signalosome to achieve activation of IKK. Binding to antigens
in the presence of costimulatory cytokines results in PKCb-mediated CARMA1 phosphorylation in B cells.ubiquitination become the key modifications that are
then used to build up a cascade of progressive oligo-
merization events that ultimately culminate in activation
of the IKK complex. The PKC isoforms that initiate this
cascade (Figure 2) are the DAG-dependent, Ca2+-inde-
pendent PKCq in T cells and the conventional DAG-
and Ca2+-dependent PKCb in B cells (Su et al., 2002;
Sun et al., 2000).
PKCq in T Cells
PKCq is predominantly expressed in skeletal muscle
and T cells and has been selectively implicated in NF-
kB and JNK activation. Among the several PKC iso-
zymes expressed in T cells (PKCb, d, 3, h, z), PKCq is
the only PKC isoform that is translocated to the cyto-
plasmic side of the cSMAC after TCR stimulation (Monks
et al., 1998); it there plays an absolutely essential role inNF-kB activation (Bi et al., 2001). PKCq is not involved
in the alternative NF-kB signaling pathway because the
induction of NF-kB by PKCq is selectively mediated by
IKKb (Li et al., 2005). In the classical NF-kB signaling
pathway, PKCq has been shown to be required for
TCR-CD28-induced degradation of IkBa and IkB3 but
not IkBb (Li et al., 2005). Inactivation of murine PKCq
confirmed the importance of this kinase in the TCR-me-
diated NF-kB pathway, leading to IL-2 transcription in
mature T lymphocytes (Sun et al., 2000). The activity of
PKCq is regulated by membrane recruitment and con-
formational changes, but the exact mechanism(s) re-
mains elusive. It is believed that PKCq catalytically ma-
tures through different phosphorylation events in a
temporally and spatially segregated manner (Sedwick
and Altman, 2004). There is also the possibility that
PKCq activity is modulated by interactions with other
Review
705Figure 2. Schematic Representation of Sig-
naling Intermediates in Antigen-Receptor-
Mediated NF-kB Activation
The number of amino acids in each human
protein is indicated on the right. Potential reg-
ulatory phosphorylation sites and functional
domains are indicated. (C1) DAG-dependent
conserved domain 1; (C2) Ca2+-dependent
conserved domain 2; (CARD) caspase-re-
cruitment domain; (PRD) PKC-regulated do-
main; (SH3) Src-homology 3 domain; (GUK)
guanylate kinase; (MAGUK) membrane-asso-
ciated guanylate kinase; (DD) death domain;
(Ig) immunoglobulin-like domain; (R) RING-
domain-type zinc finger—binds to two Zn
atoms; (TZ) TRAF-type zinc-finger domains–
binds five Zn atoms in TRAF2 and six Zn
atoms in TRAF6; (CC) coiled-coil domain;
(MATH) meprin- and TRAF-homology do-
main; (a) a-helical domain; (LZ) leucine zipper
domain; (HLH) helix-loop-helix domain;
(NBD) NEMO-binding domain; (Z) zinc finger.PKC family members through its activation-loop region,
as was shown for conventional PKCa (Trushin et al.,
2003). Vav and Lck are required for PKCq membrane
relocalization. Moreover, the physical association be-
tween PKCq and Lck in lipid rafts promotes the tyrosine
phosphorylation of PKCq on amino acid 90 (Figure 2),
which might be an important step in NF-kB activation
(Bi et al., 2001; Huang et al., 2002).
Another molecule that has been suggested to play an
important role in PKCq recruitment is the protein kinase
PDK1. Vav-dependent activation of PI3K after CD28
engagement induces PDK1 recruitment to the plasma
membrane (Figure 1); PDK1 then phosphorylates PKCq
on threonine 538 (located in the activation loop, see Fig-
ure 2) and thereby promotes the recruitment of PKCq to
the lipid rafts and PKCq’s subsequent activation (Villalba
et al., 2002; Villalba et al., 2000). Recently, we have pro-
vided evidence that PDK1 simultaneously recruits the
CBM complex through binding to CARMA1 and PKCq
(Figure 1) (Lee et al., 2005). Interestingly, it appears
that although PKCq is phosphorylated by PDK1, PKCq
in turn can also phosphorylate PDK1 (our unpublished
observation). Despite the central role played by PDK1
in TCR-induced NF-kB activation, early embryonic le-
thality of PDK1 knockouts has prevented a straightfor-
ward genetic analysis of PDK1 function in T cell activa-
tion. In addition, conditional knockout of PDK1 in the Tcell lineage via the lck-cre transgene resulted in a block
early in thymocyte development, and hence PDK1-defi-
cient T cells suitable for studying TCR signaling have not
yet been isolated (Hinton et al., 2004). Therefore, the im-
portance of PDK1 in T cell signaling remains to be estab-
lished unequivocally.
IRAK-4, a kinase that is essential for signaling from
Toll-like receptors (TLRs), may also play a critical role
in TCR-mediated activation of NF-kB (Suzuki et al.,
2006). This study proposed that upon TCR stimulation
ZAP70-associated IRAK-4 is recruited to the peripheral
SMAC and phosphorylates PKCq on threonine 538 and
that this phosphorylation facilitates PKCq-mediated
IKK activation.
Several studies suggest that PKCqmost likely contrib-
utes to the dynamic organization of the immunological
synapse by regulating the phosphorylation of actin-in-
teracting proteins, for instance WASP and moesin (Sa-
sahara et al., 2002; Thome, 2003). In addition, SAP, a pro-
tein mutated in X-linked lymphoproliferative disease
(XLP), has been implicated in TCR and SLAM corecep-
tor-mediated PKCq and BCL10 lipid-raft recruitment
(Cannons et al., 2004). Because Fyn-deficient T cells
show a phenotype similar to SAP-deficient T cells, these
findings suggest the involvement of a SAP-Fyn pathway
in the modulation of NF-kB activity in T cells. Therefore,
it appears that signals from the TCR, CD28 (through
Immunity
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such as SLAM (through SAP-Fyn) are required for effi-
cient translocation of PKCq to lipid rafts and subsequent
IKK activation.
PKCq-Deficient Mouse Models
Despite accumulating evidence, including one deficient
mouse model (by Sun et al., 2000) implicating a crucial
and selective role for PKCq in mediating NF-kB activa-
tion in response to TCR-CD28 stimulation, the exact
role played by this kinase is not completely clear. An
additional PKCq-deficient mouse model generated by
Baier and colleagues (Pfeifhofer et al., 2003) revealed
marked phenotypic differences from the knockout
mice previously reported by Littman and colleagues
(Sun et al., 2000). This mouse displayed completely ab-
rogated NFAT transactivation after CD3-CD28 engage-
ment in mature T cells, whereas NF-kB and AP1 DNA
binding in an electrophoretic mobility-shift assay were
only partially impaired (Pfeifhofer et al., 2003). Because
the genetic background of both mouse models are iden-
tical and both show impaired IL-2 secretion, the reason
for these discrepancies remains unclear. However, they
might result from differences in the targeting strategy.
Sun et al. replaced exon 11 with a PGK neo insert that
might have left a truncated 365 amino acid mutant
PKCq, whereas Pfeifhofer et al. deleted exons 3 and 4,
which left only a 9 amino acid residual open reading
frame. If there is a truncated PKCq in the mouse model
generated by Sun et al., it could function as a domi-
nant-negative inhibitor under some circumstances and
thereby affect the phenotype.
In this regard, it is interesting that a recent study im-
plies a role for PKCq in the regulation of intracellular cal-
cium concentration in primary T cells via enhancement
of PLCg activity in a positive-feedback loop, where the
Tec family kinase Itk has been proposed as the potential
link between PKCq and PLCg (Manicassamy et al.,
2006). Increased Ca2+ influx activates the phosphatase
calcineurin, which in turn activates NFAT (Altman et al.,
2004). Moreover, it was also shown that PDK1-activated
PKA promotes NFAT-dependent transcription of the T
helper 2 cytokine IL-4 in the D10 T cell line after TCR-
CD28 stimulation (Nirula et al., 2006). Because PDK1
and PKCq cooperate in NF-kB activation after TCR cos-
timulation, one might speculate that the mutant PKCq
protein in the Sun et al. study is still capable of stimulat-
ing PDK1 and thereby activating NFAT.
Conformational changes of PKCq have been sug-
gested to be a key element in the regulation of this pro-
tein kinase. The amino (N)-terminal regulatory region
with its pseudosubstrate sequence motif (Figure 2) is
important for masking the carboxy (C)-terminal ATP
binding site and thereby inactivating the catalytic kinase
domain of cytosolic PKCq under resting conditions
(Sedwick and Altman, 2004). Constitutively active mu-
tants of PKCq can therefore be generated by replace-
ment of critical alanines with glutamines (A148E or
A152E) in the pseudosubstrate motif, this leaves the cat-
alytic site free for interaction with its substrates (Baier-
Bitterlich et al., 1996). Numerous overexpression stud-
ies with this constitutively active form have established
the importance of PKCq in activating NF-kB in a T cell-
and stimulus-specific manner. Thus, the mutant proteinis not active in nonlymphoid cells, and a kinase-deficient
(K409W or K409R) form of PKCq (Figure 1) inhibits TCR-
mediated, but not TNFa- or IL-1-mediated, NF-kB activ-
ity (Coudronniere et al., 2000; Khoshnan et al., 2000; Lin
et al., 2000).
PKCq contains a number of autophosphorylation
sites, e.g., serines 676 and 695 (Figure 1), that influence
its catalytic activity (Liu et al., 2002). Serine 695 seems to
be required to trigger further phosphorylation events at
adjacent threonine 692 and 703 residues (Thebault and
Ochoa-Garay, 2004). Nevertheless, the biological role
of these posttranslational modifications of PKCq during
TCR-CD28-mediated signaling remains largely elusive.
There may be a major autophosphorylation site at thre-
onine 219. Mutation of this site to alanine (T219A) abro-
gated NF-kB, NFAT, and IL-2 promotor activation in Ju-
rkat T cells (Thuille et al., 2005). Remarkably, this site
does not affect catalytic activity or second-messenger
lipid-binding activity of PKCq in vitro, but it prevents re-
cruitment of PKCq to the immunological synapse in ac-
tivated T cells and diminishes the crosstalk between
PKCq and PKB in NF-kB activation pathways (Thuille
et al., 2005). The generation of PKCq-deficient T cell
lines, conditional knockout mice and knockin mouse
models with PKCq mutants in a PKCq-deficient back-
ground should be powerful tools for exploring the role
of phosphorylation events in the regulation of PKCq. It
is also important to test the importance of the kinase do-
main and catalytic activity of PKCq in the TCR-CD28-
mediated signaling. Finally, in ZAP70-deficient T cells,
NF-kB activity can be rescued by overexpression of
a IKKg-SH2-domain chimera, which directly targets
IKKg to the immunological synapse (Weil et al., 2003).
This suggests that TCR signaling downstream of
ZAP70 might only be necessary for proper IKK mem-
brane recruitment.
PKCb in B Cells
As described for PKCq in T cells, PKCb (Figure 2) and
IKK are recruited into lipid rafts of B lymphocytes during
BCR stimulation (Saijo et al., 2002; Su et al., 2002).
PKCb-deficient mice show diminished BCR-mediated
NF-kB activation and demonstrate a dramatic impact
on IKKa phosphorylation. Also, B cell developmental de-
fects that include reduced B cell numbers in follicular
mature and peritoneal B1 cells are observed (Su et al.,
2002). Because BCR-mediated IKK activation in PKCb-
deficient B cells cannot be rescued by phorbol ester
treatment or by CD40 coreceptor engagement, as in
Btk-deficient B cells, it has been suggested that PKCb
might act downstream of Btk (Figure 1) (Su et al., 2002).
CARMA1-BCL10-MALT1 Complex as the Central
Signaling Module in Antigen-Receptor-Induced
Activation of NF-kB
CARMA1, BCL10, and MALT1 were only recently identi-
fied as key components in the antigen receptor (AgR)-in-
duced signaling pathway that leads to NF-kB activation
downstream of PKCq and PKCb.
BCL10 was first described as a target of chromosomal
translocation in certain aggressive B cell lymphomas
(Willis et al., 1999). The resulting overexpression of
BCL10 leads to constitutive NF-kB activation, which is
a hallmark of many MALT lymphomas (Isaacson, 2005;
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family of proteins that include caspase recruitment do-
mains (CARD). Most CARD-containing proteins are in-
volved in apoptosis, and it was therefore surprising
that the phenotype of BCL10-deficient mice revealed
defects in humoral and cellular immune responses, anti-
gen-induced proliferation, and NF-kB activation in T and
B cells (Ruland et al., 2001). The BCL10-deficient mice
also exhibit impaired neuronal-tube closure and a re-
duced number of follicular and marginal-zone B cells
(Xue et al., 2003), thus implicating BCL10 not only in lym-
phocyte activation but also in neural development and
in the development of B cells (Thome, 2004). Because
there are normal numbers of peripheral T cells in
BCL10-deficient mice (Ruland et al., 2001), the role of
this adaptor protein in the development of immune cells
is still unclear and requires further analysis.
BCL10 has been reported to interact with numerous
cytoplasmic signaling molecules, including MALT1 (Lu-
cas et al., 2001; Uren et al., 2000), the CARD proteins
RIP2 (Ruefli-Brasse et al., 2004), CARMA1 (also known
as CARD11 or Bimp2) (Bertin et al., 2001; Gaide et al.,
2001; Pomerantz et al., 2002), CARMA2 (also known as
CARD14 or Bimp3) (Bertin et al., 2001), CARMA3 (also
known as CARD10 or Bimp1) (McAllister-Lucas et al.,
2001; Wang et al., 2001b), and CARD9 (Bertin et al.,
2000), and indirectly via MALT1 with TRAF6 (Sun
et al., 2004), an E3 ubiquitin ligase.
The interaction with MALT1 and oligomerization (Zhou
et al., 2004) under conditions that promote efficient
NF-kB activation produce cytoplasmic structures
called POLKADOTS (punctate and oligomeric killing or
activating domains transducing signals, Figure 1).
POLKADOTS contain both highly stable and rapidly
equilibrating protein components (Schaefer et al.,
2004). Fluorescence resonance energy transfer analy-
ses showed that POLKADOTS are sites of enhanced
interactions between BCL10 and partner signaling pro-
teins (Rossman et al., 2006). These observations
strongly suggest that POLKADOTS are focal sites of
dynamic information exchange between cytosolic inter-
mediates involved in TCR-mediated activation of NF-kB.
Another recent interesting finding is the CARMA1-
dependent BCL10-mediated activation of JNK2 leading
to elevated c-Jun transcriptional activity after TCR en-
gagement (Blonska et al., personal communication). In
this regard, BCL10 is proposed to act as a scaffold for
CARMA1, JNK2, MKK7, and TAK1.
The adaptor CARMA1 was identified by several
groups as a BCL10-interacting protein and is the only
lymphocyte-specific member of the membrane-associ-
ated guanylate kinase (MAGUK) protein family (Bertin
et al., 2001; Gaide et al., 2001; Wang et al., 2002).
CARMA1 shares with other MAGUK family members
an N-terminal CARD domain, followed by a coiled-coil
motif (CC) and a MAGUK motif containing PDZ, SH3,
and GUK domains (Figure 2) (Thome, 2004).
The targets of PKCb and PKCq in BCR- and TCR-stim-
ulated NF-kB activation pathways were unknown de-
spite intense research for a number of years. Recently,
two groups independently reported that the flexible
linker region (located between the coiled-coil and PDZ
domains) of murine CARMA1 is phosphorylated on at
least three critical serine residues (Ser-564, -649, and-657) by PKCq after TCR engagement (Matsumoto
et al., 2005) and by PKCb after BCR activation (Sommer
et al., 2005). These phosphorylation events appear to be
the critical regulatory step that controls the assembly
and oligomerization cascade of the CBM complex, al-
lows the interaction of CARMA1 with BCL10-MALT1,
and thereby triggers NF-kB activation (Figures 1 and 3).
Hence, this region of CARMA1 was termed the PKC-
regulated domain (PRD; Figure 2) (Sommer et al., 2005).
Lymphocytes from CARMA1-deficient mice (Egawa
et al., 2003; Hara et al., 2003), mice lacking the CARD do-
main of CARMA1 (Newton and Dixit, 2003), or mice with
a point mutation in the CARMA1 CC domain (‘‘unmodu-
lated,’’ L298Q substitution) (Jun et al., 2003) cannot pro-
liferate or activate the IKK complex or JNK in response
to AgR engagement. CARMA1-deficient mice exhibit
profound defects in the development or survival of B1
and NK cells, or both, as well as a complete loss of B
cell responses to lipopolysaccharide (LPS), anti-IgM,
CD40L, and BCR engagement (Hara et al., 2003). They
also show a decreased T cell response to TCR stimula-
tion (Egawa et al., 2003). In contrast, the CC domain
mutation in ‘‘unmodulated’’ mice has no effect on B
cell proliferation in response to LPS (Jun et al., 2003).
TCR-induced cell-cycle entry is also unaffected in ‘‘un-
modulated’’ mice (Jun et al., 2003), whereas it is almost
completely blocked in the CARMA1-deficient mice (Hara
et al., 2003). Other domains of CARMA1 are therefore
sufficient to mediate TCR signaling to NF-kB for the
initial response. Nevertheless, the CC domain seems
critical for the signal-enhancing and survival effects
induced by CD28 costimulation. In this respect, the
CARMA1 CC domain was proposed to be required for
CD28-mediated clustering of lipid rafts, PKCq, or a num-
ber of MAP3Ks that are implicated in CD28 signaling
to NF-kB and JNK (Kane et al., 2002a).
An enormous amount of work has been carried out to
show that CARMA1 connects PKC-derived signals to
BCL10 in the AgR-mediated activation of the IKK com-
plex (Wang et al., 2004; Wang et al., 2002; Weil and
Israel, 2004). Overexpression of CARMA1 induces
BCL10 phosphorylation and NF-kB activation (Gaide
et al., 2001), which is blocked in BCL10-deficient mice
(Ruland et al., 2001), suggesting CARMA1 is an up-
stream regulator of BCL10. A portion of CARMA1 is con-
stitutively localized within lipid rafts, interacts with
BCL10 and AgR upon stimulation, and is required for re-
cruitment of BCL10 into lipid rafts and to clustered TCR
complexes (Egawa et al., 2003; Gaide et al., 2002).
BCL10 was further shown to relocalize to the cytoplas-
mic face of the cSMAC (Schaefer et al., 2004). CARMA1
interacts with BCL10 via its CARD domain because
a CARD-domain mutant of CARMA1 (L39R) shows no
TCR-mediated binding to BCL10 or IKK activation
(Gaide et al., 2002). The inactivation of CARMA1 in cell
lines by somatic mutagenesis or RNA interference re-
sults in impaired IKK activation after TCR-CD28 stimula-
tion (Pomerantz et al., 2002; Wang et al., 2004).
Phosphorylation of the PRD region of CARMA1 by
PKCb or PKCq (Figure 1) enables CARMA1 to recruit
BCL10, TAK1, and IKKg into lipid rafts and to initiate
IKK complex activation (Matsumoto et al., 2005; Shino-
hara et al., 2005; Sommer et al., 2005). Because deletion
of the PRD from full-length CARMA1 results in high
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708Figure 3. The Antigen-Receptor-Mediated Oligomerization Cascade of the CBM Signalosome and K63-Linked Ubiquitination of IKKg Culmi-
nates in Activation of NF-kB
BCL10-MALT1 complexes from POLKADOTS are recruited to PKC-phosphorylated, trimerized, and membrane-bound CARMA1, and the formed
CBM complex proceeds to oligomerize further. TRAF2 and TRAF6 are recruited to MALT1, which trimerizes and mediates K63-linked polyubi-
quitination of IKKg (NEMO). The activated and recruited TAK1-TAB complex, possibly including RIP1 via interaction with the FADD-caspase 8
complex, phosphorylates IKKb, and this phosphorylation leads to IKK complex activation, which in turn phosphorylates IkBa and IkB3. The phos-
phorylated IkBs are polyubiquitinated by K48 chains and degraded in the 26S proteasome. Free NF-kB complexes then translocate into the
nucleus and regulate transcription of target genes.amounts of constitutively active NF-kB and because
in vitro experiments showed that the intramolecular
binding between the CARD and PRD of CARMA1 is
abolished after PKC-mediated phosphorylation (Som-
mer et al., 2005), it has been proposed that PRD
phosphorylation destabilizes an inhibitory CARMA1 con-
formation. Thus, PKC-mediated CARMA1 phosphoryla-
tion leads to an active CARMA1 conformation with
accessible protein-interaction sites (Figure 3). Mutation
of the PKC phosphorylation sites in the PRD completely
abolishes the function of CARMA1 in T cells (Matsumoto
et al., 2005). In line with this finding, constitutively active
PKCq is not able to induce NF-kB activity in CARMA1-
deficient Jurkat T cells (JPM50.6, Wang et al., 2002). Al-
together, these results provide clear evidence for the
crucial role of CARMA1 downstream of PKC and up-
stream of BCL10 in the activation of the AgR-mediated
NF-kB signal-transduction pathway.Besides CARMA1 and BCL10, the human paracas-
pase MALT1 has been identified as a caspase-like
BCL10-binding protein involved in NF-kB activation
(Lucas et al., 2001; Uren et al., 2000). MALT1 is character-
ized by an N-terminal death domain (DD) followed by two
Ig-like domains and a C-terminal caspase-like domain
(Figure 2) that is unable to cleave caspase substrates
or mediate apoptosis (Lucas et al., 2001; Uren et al.,
2000). Like BCL10, MALT1 was shown to be targeted by
chromosomal translocation in some MALT lymphomas,
resulting in a chimeric fusion protein between the C ter-
minus of MALT1 and the N-terminal portion of cIAP2
(an anti-apoptotic protein), which activates NF-kB
(Uren et al., 2000). Under physiological circumstances,
BCL10 and MALT1 physically and functionally interact
to synergistically activate NF-kB after AgR engagement.
One interaction occurs 13 amino acids downstream of
the BCL10 CARD with the Ig-like domain of MALT1
Review
709(Lucas et al., 2001). An additional interaction between
the helix 5–6 region of the BCL10 CARD and the MALT1
N terminus has been reported, and the DD of MALT1
contributes to this interaction (Langel et al., personal
communication). It is possible that an unknown partner
protein contacts and bridges both molecules. Together,
these data demonstrate that the functionally critical as-
sociation between BCL10 and MALT1 involves a com-
plex interaction between multiple protein domains.
Two groups have reported conflicting results in inde-
pendently generated MALT1-deficient mice (Ruefli-
Brasse et al., 2003; Ruland et al., 2003). Although both
show a defect in cellular proliferation, IL-2 production
and IKK activation after TCR stimulation, as well as the
absence of defects during neurodevelopment (in con-
trast to the phenotype of BCL10-deficient mice), they
differ in the requirement of MALT1 for AgR-dependent
JNK activation and BCR-mediated NF-kB activation.
The reason for this difference is unclear, but the differ-
ence may once again be due to the different targeting
strategies used.
In summary, the importance of CARMA1 in transmit-
ting the PKC-derived AgR-initiated signal to the IKK
complex is to act as a scaffold to allow assembly of
the important signaling intermediates BCL10, MALT1,
and IKKg for activation of NF-kB in immune cells. This
CARMA1-nucleated complex has been termed the
CBM or CARMA1 signalosome (Rawlings et al., 2006).
Regulation of CBM Signalosome Recruitment
and Activity
Although a fraction of CARMA1 resides constitutively in
lipid rafts, at least in B cells, there is rapid and substan-
tial recruitment of additional CARMA1 to lipid rafts after
AgR stimulation (Sommer et al., 2005). The SH3 domain
of CARMA1 might be of particular importance for trans-
location to lipid rafts because a CARMA1 mutant lacking
this region fails to be recruited to lipid rafts in Jurkat
T cells (Wang et al., 2002).
The N-terminal proline-rich region of PDK1, a serine-
threonine kinase that was shown to recruit CARMA1
and PKCq into lipid rafts after CD3-CD28 costimulation
in Jurkat T cells, seems to be a likely target site for the
CARMA1 SH3 domain (Lee et al., 2005). PDK1 and
maybe other unknown adaptor proteins bring PKCq
and CARMA1 into close proximity, facilitating PKC-me-
diated CARMA1 phosphorylation and consequent acti-
vation (Matsumoto et al., 2005). CARMA1 then oligomer-
izes, likely via its CC domain (Figure 2) because this is
the principal oligomerization motif (Burkhard et al.,
2001). CARMA1 is thought to oligomerize first as a trimer,
which triggers a downstream oligomerization cascade
(Figure 3) that is ultimately necessary for recruitment
of IKK to the SMAC and IKK’s subsequent activation
(Hara et al., 2004; Sun et al., 2004). Because the GUK do-
main in other MAGUK-family proteins mediates homo-
typic oligomerization, a similar role for the CARMA1 MA-
GUK region has been proposed (Rawlings et al., 2006).
The latter could amplify the AgR signal by facilitating
higher-order multimerization of CARMA1 proteins.
Several lines of evidence support an essential role of
such a CBM-signalosome-induced oligomerization cas-
cade in IKK activation: (1) Oligomerization of CARMA1,
BCL10, or MALT1 is sufficient to induce downstreamsignaling for IKK activation (Newton and Dixit, 2003; Sri-
nivasula et al., 1999; Stilo et al., 2004; Sun et al., 2004);
(2) overexpression of several of the CBM-signalosome
components results in their spontaneous oligomeriza-
tion in cells or in vitro (Guiet and Vito, 2000; Rawlings
et al., 2006; Srinivasula et al., 1999); and (3) Overexpres-
sion of CARMA1, BCL10, MALT1, or TRAF6 alone is suf-
ficient to induce IKK activation in the absence of other
stimuli (Bertin et al., 2001; Gaide et al., 2001; Ruefli-
Brasse et al., 2003; Willis et al., 1999; Zhou et al., 2004).
After CARMA1 activation and oligomerization, BCL10
gets recruited to the signalosome through a CARD-
CARD interaction. Deletion of either the CARMA1
CARD or the BCL10 CARD domain abolishes AgR-medi-
ated IKK activation (Bertin et al., 2001; Gaide et al., 2002).
The mechanism by which BCL10 activity is regulated in
the CBM signalosome is not fully understood. A number
of studies have suggested that it involves phosphoryla-
tion events, but these findings are somewhat controver-
sial because BCL10 phosphorylation has been sug-
gested to have positive as well as negative effects on
IKK activation. The kinase Receptor Interacting Protein
(RIP) 2 can associate with and phosphorylate BCL10 in
response to TCR costimulation (Ruefli-Brasse et al.,
2004). RIP2 is a C-terminal CARD-containing serine-
threonine kinase that is required for optimal TCR-medi-
ated NF-kB activation and IL-2 production as well as
T cell proliferation and Th1 differentiation (Chin et al.,
2002; Kobayashi et al., 2002). Interestingly, because
RIP2 also plays an important role in innate immune path-
ways, it is possible that the CBM signalosome might in-
tegrate signals of the adaptive and innate immune sys-
tems by regulating pathways that lead to the activation
of NF-kB. It is possible that BCL10 gets phosphorylated
by RIP2 or other kinases in the cytosolic POLKADOTS
and that this phosphorylation allows subsequent trimeri-
zation and association with MALT1 (Figure 1). The region
between amino acids 107 and 119 of BCL10 can bind to
the two Ig-like domains of MALT1 (Lucas et al., 2001), the
BCL10-MALT1 complex can be recruited to the acti-
vated oligomerized CARMA1 (Figure 3), and further-
more, as-yet-uncharacterized modifications of BCL10
can lead to oligomerization of the CBM complex.
CBM Signalosome and TRAF in IKK Activation
A breakthrough in deciphering the connection be-
tween the CBM signalosome and IKK came with the
discovery that BCL10-MALT1 mediates Lys-63-linked
polyubiquitination of IKKg in a ubiquitin-conjugating en-
zyme 13 (UBC13)-dependent manner (Zhou et al., 2004).
In parallel, TRAF2 and TRAF6 (Figure 2), which play cen-
tral roles in the innate immune responses, were impli-
cated as proximal downstream effectors of MALT1 and
were found to possibly have redundant functions in
AgR-mediated NF-kB signaling (Sun et al., 2004). Inter-
action with the oligomerized MALT1 activates TRAF6,
and possibly TRAF2, most likely by conformational
changes and stabilization of a trimerized TRAF complex
(Park et al., 1999). Indeed, it was shown that TRAF olig-
omerization is sufficient to induce IKK activation (Baud
et al., 1999). Moreover, small interfering RNA (siRNA)
depletion of TRAF6, and also TRAF2, abolished TCR-
induced IKK activation (Sun et al., 2004). Nevertheless,
although the requirement of TRAF6 in TCR-mediated
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TRAF2 is less well characterized. The minimal signaling
pathway from activated BCL10 to IkBa phosphorylation
has been reconstituted in vitro and consists of MALT1,
the E3 ligase TRAF6, the E2 dimer UBC13 ubiquitin-con-
jugating enzyme E2 variant 1a (UEV1a), E1, ubiquitin, the
TAK1 complex, and the IKK complex (Sun et al., 2004).
However, further work will be required to definitively
solve the spatial and temporal roles of these proteins
in IKK-complex activation.
TRAF6, and possibly TRAF2, contribute to IKK activa-
tion in T cells (Figure 3). Activated TRAF2 potentially tar-
gets RIP1 for K63 polyubiquitination, whereas activated
TRAF6 is auto-K63 polyubiquitinated and mediates K63
polyubiquitination of IKKg at lysine 399, thereby facili-
tating IKK activation (Sun et al., 2004). IKK activation is
thought to involve binding between ubiquitinated
TRAF6, the TAK1 complex consisting of TAK1, and one
or more TAK1 binding proteins (TAB1-3) and the IKK
complex (Rawlings et al., 2006). The exact binding part-
ners and domains responsible are presently unknown,
but one possible mechanism involves binding of TAK1
to TRAF6, leading to K63 polyubiquitination of IKKg.
Activated TAK1 in the complex could phosphorylate
IKKb on serine residues 177 and 181 and thus activate
IKK kinase activity, leading to IkBa phosphorylation and
NF-kB activation (Wang et al., 2001a). In chicken DT40 B
cells, TAK1 is essential for IKK activation in response to
BCR stimulation (Shinohara et al., 2005). TAK1 was
shown to interact with PKCb-phosphorylated CARMA1,
placing TAK1 in the CBM signalosome in close proximity
with the IKK complex and thereby making it capable of
phosphorylating IKKb (Shinohara et al., 2005). However,
this general model has been challenged in two studies in-
volving conditional TAK1-deficient mice. These studies
showed normal IKK activation after AgR stimulation in
B cells and effector T cells but impaired JNK activation
in B cells (Sato et al., 2005; Wan et al., 2006). Never-
theless, TAK1 was clearly shown to be required for TCR-
induced NF-kB activation in naı¨ve T cells and thymo-
cytes (Liu et al., 2006; Sato et al., 2006; Wan et al., 2006).
TRAF2 catalyzes RIP1 K63 polyubiquitination, and
RIP1 could in turn associate with the TAK1 complex or
with the FADD-caspase 8 complex and thereby activate
NF-kB (Ishizawa et al., 2006; Su et al., 2005). Thus, the
FADD-caspase 8 complex may bridge the CBM signalo-
some and IKKa-IKKb and thereby allow phosphorylation
of the IKK complex through RIP1 (Figure 3). However, in
B cell-specific conditional caspase 8-deficient mice,
there was no defect in NF-kB activation in response to
BCR stimulation (Beisner et al., 2005). In addition,
UBC13-deficient B cells showed almost normal NF-kB
activation but impaired activation of JNK and p38
MAPKs after AgR stimulation (Yamamoto et al., 2006).
Therefore, although there is a large body of in vitro
biochemical and cell-culture experiments that implicate
regulatory ubiquitination in AgR signaling to NF-kB,
there is currently less convincing genetic evidence sup-
porting such an essential role for regulatory ubiquitina-
tion in these signaling pathways. Clearly, further work
will be necessary to clarify the role of UBC13 in TCR-
mediated NF-kB activation and to determine whether
other E2 ubiquitin-conjugating enzymes compensate
for the absence of UBC13 in transferring K63-linkedpolyubiquitin chains from the CBM signalosome to the
IKK complex.
Downregulation and Modulation of the
AgR-Mediated IKK Activation
Downregulation of signaling after engagement of AgR
utilizes multiple strategies, including well-characterized
pathways involving receptor internalization. Indeed,
PKCq participates in downregulation of activated TCRs
by the TCR-recycling pathway through phosphorylation
of serine 126 and the di-leucine-based receptor-sorting
motif of the CD3g chain (Figure 4) (von Essen et al., 2006).
Additionally, the termination of AgR-mediated NF-kB-
activation pathways also involves active mechanisms
such as the degradation of key signaling molecules. It
has been shown that the amount of BCL10 protein is
markedly reduced after AgR signaling in a process de-
pendent on the CARD domain of BCL10. NEDD4, Itch,
and cIAP2 protein mediate ubiquitination of BCL10
and its subsequent lysosomal degradation, thus down-
modulating NF-kB activation (Hu et al., 2006; Scharsch-
midt et al., 2004). Attachment of single ubiquitin mole-
cules, rather than ubiquitin chains, to one or multiple
lysines is sufficient to target proteins to a complex sort-
ing apparatus on the endosome. This machinery selects
ubiquitinatedproteins for lysosomalsorting throughcon-
secutive interactions with a variety of ubiquitin-binding
domains (Urbe, 2005). Interestingly, the cIAP2-BCL10
interaction appears to be regulated by BCL10 phosphor-
ylation; phosphorylated BCL10 is bound much more
strongly to cIAP2 than is unphosphorylated BCL10 (Hu
et al., 2006). Upon T cell costimulation, CBM-signalo-
some-activated IKKb phosphorylates the C terminus
of BCL10 and thereby disrupts association between
BCL10 and MALT1 (Wegener et al., 2006) (Figure 4).
An additional strategy of downregulating NF-kB-acti-
vating pathways is through deubiquitination of K63-
linked polyubiquitin chains by proteins such as the tu-
mor suppressor cylindromatosis protein (CYLD) and
A20, which have been up to now mainly studied in sig-
naling pathways triggered during the innate immune
response (Rawlings et al., 2006). CYLD was shown to in-
activate TRAF2, TRAF6, and IKKg by removing the K63-
linked polyubiquitin chains (Kovalenko et al., 2003),
whereas A20 removes K63-linked polyubiquitin chains
from TRAF2, TRAF6, and RIP1 (Wertz et al., 2004). A20
also catalyzes K48-linked polyubiquitination of RIP1
and targets it for proteasomal degradation. Because
TRAF2, TRAF6, and RIP1 have also been reported to
function in lymphocyte-activation pathways, one might
speculate that similar downregulatory pathways could
operate in lymphocytes. However, this hypothesis
needs to be proven experimentally.
The life and death of peripheral lymphocytes is strictly
controlled to maintain appropriate numbers of T and B
cells. Activation-Induced Cell Death (AICD) is a form of
apoptosis that is of pivotal importance for the termina-
tion of the immune response and, therefore, homeosta-
sis of the immune system. Although initial stimulation of
peripheral primary T cells leads to proliferation, restimu-
lation of expanded T cells results in AICD. The hemato-
poietic progenitor kinase (HPK) 1 was characterized as
an immunoreceptor proximal signaling protein (Liou
et al., 2000) involved in the regulation of AICD in primary
Review
711Figure 4. Downregulation of the CBM Signalosome and IKK Activity
The antigen-receptor-mediated signal to NF-kB is downregulated to keep the immune cells responsive. Activated IKKb phosphorylates BCL10,
and this phosphorylation leads to dissociation of the BCL10-MALT1 complex, where cIAP2, Itch, and NEDD4 ubiquitination of phosphorylated
BCL10 leads to lysosomal degradation of BCL10. RIP1 also undergoes polyubiquitination by K48 chains and is degraded in the proteasome.
PKCq was shown to play a role in downregulation of directly engaged TCR. In a feedback loop, newly synthesized IkB binds to nuclear NF-
kB and thus removes it from DNA and exports it to the cytosol. During activation-induced cell death (AICD), the C-terminal cleavage product
of HPK1 binds to inactive IKKa and IKKb, which then sequester the IKK complex in the cytosol and thereby inhibit NF-kB.T cells (Brenner et al., 2005; Schulze-Luehrmann et al.,
2002). Although the full-length serine-threonine kinase
is activated by AgR engagement and recruited into lipid
rafts, where it has been shown to activate JNK and en-
hance IKKbphosphorylation, the C-terminal HPK1 cleav-
age product that is generated in AICD-sensitive primary
T cells sequesters the IKK complex by binding to IKKa-
IKKb, and its binding thus leads to inhibition of TCR-
mediated NF-kB activation (Brenner et al., 2005). Fur-
thermore, the cleaved N-terminal kinase domain of HPK1
can continue to activate JNK and thus further promote
apoptosis of T cells (Schulze-Luehrmann et al., 2002).
Concluding Remarks
In antigen-stimulated lymphocytes, NF-kB controls the
expression of multiple genes essential for survival, pro-
liferation, and effector function. Signaling by AgR directs
lymphocyte development at crucial checkpoints to
shape the immune repertoire (Hayden et al., 2006). Tre-mendous progress has been made in the past few years
in understanding the details of AgR-mediated activation
and regulation of NF-kB. Such advances have included
the discovery of the crucial role of the CARMA1-
BCL10-MALT1 complex and the role of oligomerization,
ubiquitination, and phosphorylation events in immuno-
receptor-mediated IKK and JNK activation.
Aberrant NF-kB signaling is an area of particularly in-
tensive investigation because of the link between consti-
tutive activation of NF-kB and various lymphomas and
myelomas. Upregulation of both PKCb and CARMA1 is
detectable in different lymphomas (Hans et al., 2005;
Nakamura et al., 2005; Ngo et al., 2006), and constitutive
NF-kB activation due to chromosomal translocations of
MALT1 and BCL10 genes is a causative event in MALT
lymphomas (Farinha and Gascoyne, 2005; Isaacson,
2005; Karin, 2006). Therefore, pharmacological agents
directed against PKCq in T cells, against PKCb in B cells,
or against specific components of the CBM signalosome
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tolerance or for treatment of certain autoimmune disor-
ders and lymphoid malignancies. In this respect, it is in-
teresting to note that PKCq-deficient mice are resistant
to Th1-dependent antigen-induced arthritis (Healy
et al., 2006), whereas CARMA1 was shown to be critical
for the development of allergic airway inflammation in
a murine model of asthma (Medoff et al., 2006).
In conclusion, despite the tremendous progress made
in understanding how antigen receptors link to the IKK
complex, a number of important, outstanding questions
remain. For example, the precise functions of RIP2,
TAK1, TRAF2 and TRAF6, BCL10 phosphorylation, and
POLKADOT formation in the AgR-mediated signaling
cascade to NF-kB activation remain to be fully clarified.
Especially the specific roles for TRAF2 and TRAF6 in
BCR signaling remain elusive. Many of the molecules in-
volved in AgR-mediated NF-kB activation (PKCq, PKCb,
CARMA1, RIP2, TAK1 complex) also play important
roles in JNK activation. It is therefore crucial to identify
the exact point of divergence between these two path-
ways and to clarify whether and how components
specific for JNK activation are recruited into the CBM
signalosome. This is particularly true because JNK and
NF-kB can control the apoptotic response in an antago-
nistic manner. In B cells the coupling between the NF-kB
and JNK pathways is important for the antigenic re-
sponse because uncoupling both signal transduction
pathways leads to clonal anergy, whereas the tolero-
genic response to antigens in T cells is characterized
by impaired JNK and NF-kB activation. Thus, the immu-
nological response to pathogens is the result of a pre-
cisely balanced interaction among adaptors, kinases,
other enzymes, and their downstream targets, and it is
clear that the pathway leading to NF-kB plays an essen-
tial and central role.
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